Ernexa Therapeutics Inc.

Ernexa Therapeutics Inc. is a preclinical-stage cell therapy company developing synthetic allogeneic iMSC (induced pluripotent stem cell-derived mesenchymal stem cell) therapies. Its lead program, ERNA-101, is designed to deliver immune-stimulating cytokines into the tumor microenvironment, with an initial focus on platinum-resistant ovarian cancer and a broader pipeline in autoimmune disease.

−1 590,0 %

83,5 %

−2 419,9 %

1.01

1.01

— Ernexa Therapeutics Inc.
%
Lead therapeutic programs0% Preclinical cell therapy candidates designed to modulate immune responses in cancer and autoimmune disease.
Cell line customization services100% Custom development of induced pluripotent stem cell lines for a customer under a contract arrangement.
Licensing and collaboration arrangements0% Option, sublicense, and partnership structures intended to monetize platform technology and future assets.
Research and development services0% Preclinical research, assay development, and partner-supported development activities.

Ernexa’s direct customers have been limited and contract-based, including a customer for exclusive option/licensing...

  • Pharmaceutical and biotechnology partnersprimary

    Potential licensees or co-development partners that would pay for access to the iMSC platform and pipeline assets.

  • Custom cell line customersecondary

    A contract customer that paid for iPSC line customization and related option/licensing rights.

  • Academic research collaboratorssecondary

    Institutions such as MD Anderson that support preclinical validation and translational work.

  • Grant and non-dilutive capital providersemerging

    Public or private funding sources that support research activities and reduce dilution.

Ernexa is headquartered in the United States and appears to conduct most of its operations there, including research...

  • •United States is the core operating base and corporate headquarters
  • •Texas subsidiary supports research activity and grant-funded work
  • •Japan is a strategic target for future clinical and commercial entry
  • •No disclosed country revenue mix; company currently has no ongoing revenue contracts
  • •Geographic exposure is mainly operational and regulatory, not sales-driven

The company’s near-term strategy is to advance ERNA-101 through IND-enabling work, submit an IND in 2026, and begin a...

01
Advance ERNA-101 into clinical testingshort-term

Clinical entry is the key value inflection point for a preclinical biotech and validates the platform beyond lab data.

02
Secure external funding and partnershipsshort-term

The company has stated it lacks sufficient capital for the next 12 months and needs non-dilutive or dilutive funding to continue operations.

03
Build a broader iMSC pipelinemedium-term

A second program such as ERNA-201 can broaden the platform beyond oncology and improve partnering appeal.

Ernexa is a development-stage biotech with no commercial product revenue and a stated going-concern risk, so financing...

critical

Insufficient capital to fund operations

Management disclosed it will not have sufficient capital for the next 12 months without additional financing.

Scope
Corporate survival and program continuity
Materiality
high
high

Clinical development failure

ERNA-101 is preclinical and may fail in IND-enabling studies, human trials, or later efficacy testing.

Scope
Lead asset value and partnering prospects
Materiality
high
high

Competitive displacement in ovarian cancer

Approved and late-stage therapies may reach the market before Ernexa, limiting adoption and pricing power.

Scope
Platinum-resistant ovarian cancer indication
Materiality
high
medium

Nasdaq continued listing compliance

The company disclosed risk of delisting if it fails minimum bid price or equity requirements.

Scope
Public market access and liquidity
Materiality
medium
Revenue recognition on customization and licensing contracts
Affects reported revenue and cost of revenues
Research and development expense recognition
Affects operating loss and comparability across periods
Goodwill impairment
Could create non-cash charges and reduce equity
Fair value of debt and equity-linked instruments
Can materially affect net loss and volatility

Estrella Immunopharma, Inc.

ESLA · Biological Products, (No Diagnostic Substances)

Oncotelic Therapeutics, Inc.

OTLC · Pharmaceutical Preparations

Erasca, Inc.

ERAS · Pharmaceutical Preparations

Theriva Biologics, Inc.

TOVX · Pharmaceutical Preparations

Neurogene Inc.

NGNE · Pharmaceutical Preparations

TuHURA Biosciences, Inc./NV

HURA · Pharmaceutical Preparations

: 28/04/2026